AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 25, 2024
Illustrative example of damaged skin, in this case from sunburn. (Jennifer A Smith/Getty Images) A rare and potentially fatal skin infection with nightmarish outcomes may soon have a cure.
Bio Pharma Dive
NOVEMBER 25, 2024
Positive results from a study of Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent expirations this decade.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
NOVEMBER 26, 2024
In an article published online this week , leaders from the NIH Pragmatic Trials Collaboratory share lessons learned about the collection of patient-reported outcome measures (PROMs) in medically underserved patients, including people with incomes below the federal poverty threshold, racial or ethnically minoritized groups, and rural and frontier communities.
Pharmaceutical Technology
NOVEMBER 26, 2024
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
NOVEMBER 25, 2024
Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. | In the phase 3 ZENITH study, Merck’s activin signaling inhibitor Winrevair met its primary endpoint of time to first morbidity or mortality event, which included all-cause death, lung transplantation, or hospitalization for at least 24 hours linked to disease worsening in patients with PAH.
Bio Pharma Dive
NOVEMBER 26, 2024
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 27, 2024
Pharmaceutical professionals expect digital solutions to solve drug development headaches, with AI already proving disruptive.
Rethinking Clinical Trials
NOVEMBER 25, 2024
Drawing on experiences from the NIH Collaboratory Trials, authors of a new article in Contemporary Clinical Trials describe the challenges they encountered when relying on data from the electronic health record (EHR) to monitor outcomes and deliver interventions in pragmatic clinical trials embedded in healthcare systems. “Teams need to be aware of—and perhaps proactively investigate—possible changes to EHR systems and data that will affect the delivery of interventions and the integrity and saf
Bio Pharma Dive
NOVEMBER 27, 2024
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue forecast for its schizophrenia and depression medicine Caplyta.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 28, 2024
Cardiac muscle cells in mice. (Martens et al., The Lancet, 2024) Popular weight loss drugs like Ozempic and Wegovy are showing incredible short-term benefits – from boosted metabolic health to pain relief to addiction and cognitive health.
Pharmaceutical Technology
NOVEMBER 27, 2024
In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic conditions such as rheumatoid arthritis and psoriasis, where biologics have also transformed treatment paradigms.
Deltaclinical
NOVEMBER 25, 2024
In September 2024, the FDA released a document regarding the conduct of clinical trials with decentralized elements.
Bio Pharma Dive
NOVEMBER 25, 2024
The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 28, 2024
The Pharmacy Council of India (PCI) has sought all the pharmacists who don’t have the ABHA (Ayushman Bharat Health Account) number to attain a number and ensure registration with the DIGI-PHARMed profile with the ABHA number on immediate basis, as part of its efforts to integrate the pharmacists’ list with the Healthcare Professional Registry (HPR).
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
NOVEMBER 29, 2024
The government said that men are less likely than women to seek medical help, particularly for mental health issues.
Medical Xpress
NOVEMBER 29, 2024
Emotional body odors may have the potential to enhance the anxiety-reducing effects of mindfulness. This is shown by a pilot study published in the Journal of Affective Disorders, co-authored by researchers from Karolinska Institutet.
Bio Pharma Dive
NOVEMBER 26, 2024
The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing share price on Monday.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 26, 2024
(SciePro/Science Photo Library/Getty Images) Stem cells are special in the way they can keep on replicating, and turn themselves into many other types of cell. Now scientists have discovered how their superpowers get a remarkable boost when they’re grown in space.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
NOVEMBER 28, 2024
The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.
Fierce Pharma
NOVEMBER 25, 2024
Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and Retraining Notification (WARN) update.
Bio Pharma Dive
NOVEMBER 26, 2024
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 27, 2024
The hypertension drug rilmenidine has been shown to slow down aging in worms, an effect that in humans could hypothetically help us live longer and keep us healthier in our latter years. Previous research has shown rilmenidine mimics the effects of caloric restriction on a cellular level.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
NOVEMBER 29, 2024
The ESMP platform enables marketing authorisation holders to report shortages and will be mandatory from 2025.
Fierce Pharma
NOVEMBER 25, 2024
Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol Myers Squibb's Revlimid and Roche's Rituxan—triggered a 57% reduction in the risk of disease progression, relapse or death in R/R FL patients compared with those who were treated with placebo, Revlimid and Rituxan.
Bio Pharma Dive
NOVEMBER 27, 2024
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 26, 2024
The Indian Council of Medical Research (ICMR) has announced an open call for proposals under its Centre for Advanced Research (CAR) scheme to support clinical studies for medical device and diagnostic technologies developed through the ICMR-DHR-Centre of Excellence (CoEs) programme at various IITs.
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
Pharmaceutical Technology
NOVEMBER 28, 2024
There are currently no FDA- or EMA-approved treatment options available for any form of frontotemporal dementia.
Fierce Pharma
NOVEMBER 26, 2024
While Novartis has largely wrapped up its transformation into a leaner innovative medicines company—which included multiple rounds of staff cuts over the years—employment changes are still afoot at | Novartis is laying off a total of 139 staffers in East Hanover, New Jersey, where the company’s U.S. headquarters is located. The move will primarily affect commercial field sales associates working on the brands Xolair for asthma and allergies and the oncology combo made up of kinase inhibitors Taf
Bio Pharma Dive
NOVEMBER 27, 2024
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 25, 2024
Digital technologies have transformed biology research to provide in-depth insights into unravelling the mysteries of living systems. Bioengineering is the new frontier in advanced technology, said Kiran Mazumdar-Shaw, chairperson, Biocon Group and Association of Biotechnology Led Enterprises (ABLE). Genetic engineering has unleashed a power house of bio manufacturing in the fermentation industry.
Expert insights. Personalized for you.
204 
Let's personalize your content